Disclosure Panels Details Page
Soft Tissue Sarcoma Panel - Disclosures as of 11/27/2012
|
Panel Member
(Spouse/Domestic Partner/Dependent) |
Clinical Research Support/Data Safety Monitoring Board | Scientific Advisory Boards, Consultant, or Expert Witness | Promotional Advisory Boards, Consultant, or Speakers Bureau | Employment/ Governing Board, Patent, Equity, or Royalty | Has Attended |
|---|---|---|---|---|---|
| Robert Benjamin MD | Amgen Inc. | Amgen Inc. | None | Johnson & Johnson|Merck & Co., Inc.|Pfizer Inc. | ✔ |
| Marilyn Bui MD, PhD | None | Novartis Pharmaceuticals Corporation | None | None | ✔ |
| Ephraim Casper MD | None | None | None | None | ✔ |
| Ernest Conrad III MD | None | None | None | None | - |
| Thomas DeLaney MD | None | None | None | None | ✔ |
| Lauren Gallagher | None | None | None | None | - |
| Kristen Ganjoo MD | None | None | None | None | ✔ |
| Suzanne George MD | Bayer HealthCare Eisai Inc. Johnson & Johnson |
Pfizer Inc. | None | None | ✔ |
| Ricardo Gonzalez MD | None | None | None | None | ✔ |
| Kristina Gregory MSN, RN | None | None | None | None | - |
| Martin Heslin MD | None | None | None | None | - |
| John Kane III MD | None | None | None | None | - |
| Joel Mayerson MD | Millennium Pharmaceuticals, Inc. | None | None | None | ✔ |
| Joan McClure MS | None | None | None | None | - |
| Sean McGarry MD | None | None | None | Musculoskeletal Transplant Foundation | ✔ |
| Nicole McMillian MS | None | None | None | None | - |
| Christian Meyer MD, PhD | None | None | None | None | ✔ |
| Richard O`Donnell MD | None | None | None | None | ✔ |
| I. Benjamin Paz MD | Agendia BV | None | None | None | ✔ |
| John Pfeifer MD, PhD | None | None | None | None | ✔ |
| Raphael Pollock MD, PhD | None | None | None | None | - |
| R. Lor Randall MD, FACS | None | Amgen Inc. Biomet, Inc. Musculoskeletal Tumor Society |
None | None | ✔ |
| Richard Riedel MD | ARIAD Pharmaceuticals, Inc. Astex Pharmaceuticals CytRx Corporation Eisai Inc. GSK Infinity Pharmaceuticals Novartis Pharmaceuticals Corporation Threshold |
Novartis Pharmaceuticals Corporation | None | None | ✔ |
| Scott Schuetze MD, PhD | AB Sciences Amgen Inc. Johnson & Johnson Novartis Pharmaceuticals Corporation SARC Ziopharm |
DAVA pharmaceuticals Novartis Pharmaceuticals Corporation Ziopharm |
None | None | ✔ |
| Karen Schupak MD | None | None | None | None | - |
| Herbert Schwartz MD | None | None | None | Musculoskeletal Transplant Foundation | ✔ |
| Sheri Spunt MD | None | None | None | None | ✔ |
| Hema Sundar PhD | None | None | None | None | - |
| Brian Van Tine MD, PhD | None | Bayer HealthCare | None | None | ✔ |
| Margaret Von Mehren MD | Arog Pharmaceuticals Astex Pharmaceuticals Eisai Inc. Infinity Johnson & Johnson Merck & Co., Inc. Morphotek Inc. National Cancer Institute Novartis Pharmaceuticals Corporation OSI Pharmaceuticals, Inc. Pfizer Inc. Pharma Mar Sarcoma Alliance for Research through Collaboration Synta Pharmaceuticals Corp. |
Eisai Inc. Merck & Co., Inc. Novartis Pharmaceuticals Corporation Pfizer Inc. Pharma Mar |
None | None | ✔ |
| Jeffrey Wayne MD | None | Novartis Pharmaceuticals Corporation | None | None | ✔ |